Skip NavigationSkip to Content
Return Return to Search Results

Efficacy of oral recombinant methioninase combined with oxaliplatinum and 5-fluorouracil on primary colon cancer in a patient-derived orthotopic xenograft mouse model

  1. Author:
    Park, Jun Ho
    Zhao, Ming
    Han, Qinghong
    Sun, Yu
    Higuchi, Takashi
    Sugisawa, Norihiko
    Yamamoto, Jun
    Singh,Shree Ram
    Clary, Bryan
    Bouvet, Michael
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Surgery, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea., AntiCancer Inc, San Diego, CA, USA., AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., AntiCancer Inc, San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2019
    2. Date: Oct 15
    3. Epub Date: 2019 08 14
  2. Journal: Biochemical and biophysical research communications
    1. 518
    2. 2
    3. Pages: 306-310
  4. Type of Article: Article
  5. ISSN: 0006-291X
  1. Abstract:

    The aim of this study was to determine the efficacy of oral recombinant methioninase (o-rMETase) on a colon cancer primary tumor using a patient-derived orthotopic xenograft (PDOX) nude mouse model. Forty colon cancer primary tumor PDOX mouse models were divided into 4 groups of 10 mice each (total 40 mice) by measuring the tumor size. The groups were as follows: untreated control; 5-fluorouracil (5-FU) (50 mg/kg, once a week for two weeks, N = 10 mice) and oxaliplatinum (OXA) (6 mg/kg, once a week for two weeks, N = 10 mice); o-rMETase (100 units/day, oral 14 consecutive days, N = 10 mice); combination of 5-FU + OXA and o-rMETase (N = 10 mice). All treatments inhibited tumor growth compared to the untreated control. The combination of 5-FU + OXA and o-rMETase was significantly more efficacious than other treatments. The present study demonstrates the efficacy of o-rMETase combination therapy on a PDOX colon cancer primary tumor, suggesting potential clinical development of o-rMETase in recalcitrant cancer. Published by Elsevier Inc.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.bbrc.2019.08.051
  3. PMID: 31421825
  4. View record in Web of Science®
  5. WOS: 000506401900018
  6. PII : S0006-291X(19)31568-2

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel